Dr Reddy's hits record high on migraine drug launch in US

Shares in Dr Reddy's Laboratories rose as much as 2.1 percent to a record high on growing hopes about its U.S. business.

The drug maker said late on Tuesday that it launched Sumatriptan injection, used for migraine, for U.S. markets.

Separately, Macquarie upgraded its price target for Dr. Reddy's shares to 3,325 rupees from 3,200 rupees, saying its U.S. business was "significantly under appreciated by the street."

The ramp-up of key products in the United States, including planned launches in fiscal 2015, would help boost sales, Macquarie added.

Shares in the company were up 1.8 percent at 1:18 p.m.

The gains come in contrast to rivals such as Ranbaxy Laboratories Ltd, which has slumped 21 percent since January 11 because of U.S. regulatory issues. In contrast, Dr. Reddy's has gained 5.6 percent during the same period.


  • Banks have been reluctant to transmit RBI policy rate cuts to borrowers

    Banks have been slow in passing the benefit of repo rate cuts by the central bank to their borrowers.


Stay informed on our latest news!


Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs


Arun Nigavekar

Ranking of higher education institutions

Given the massive popularity and growing influence of world university ...

Rajgopal Nidamboor

The pursuit of serene stillness

It may sound strange — that every change in the ...

Dharmendra Khandal

How positive intervention can go a long way

Ten years ago, Sariska tiger reserve declared that there were ...


William D. Green

Chairman & CEO, Accenture